Live Earnings Conference Call: Harrow will host a live Q1 2026 earnings call on May 12, 2026 at 8:00AM ET. NASDAQ:HROW Harrow Q1 2026 Earnings Report $38.04 -0.19 (-0.50%) Closing price 05/11/2026 04:00 PM EasternExtended Trading$33.88 -4.17 (-10.95%) As of 07:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Live Call not available Upcoming EventEarnings Conference CallHarrow Q1 202600:00 / 00:00Live Transcript Follow Audio Harrow EPS ResultsActual EPS-$0.74Consensus EPS -$0.43Beat/MissMissed by -$0.31One Year Ago EPS-$0.38Harrow Revenue ResultsActual Revenue$44.20 millionExpected Revenue$52.43 millionBeat/MissMissed by -$8.22 millionYoY Revenue GrowthN/AHarrow Announcement DetailsQuarterQ1 2026Date5/11/2026TimeAfter Market ClosesConference Call DateTuesday, May 12, 2026Conference Call Time8:00AM ETConference Call ResourcesSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Harrow Earnings HeadlinesHarrow Announces First Quarter 2026 Financial ResultsMay 11 at 11:03 PM | markets.businessinsider.comIs Harrow (HROW) Pricing Reflect Its 65.5% One Year Surge And DCF OutlookMay 10 at 2:46 PM | finance.yahoo.comMusk’s Next $4 Trillion Takeover Target – It’s Stranger than you ThinkTech analyst Ian King - who called an early Tesla trade that returned up to 1,000% in just over a year - says a single move by Elon Musk could reshape the monetary system within weeks. King has released a new presentation outlining what he believes is one of the most significant wealth-building opportunities in decades, and it's available free of charge right now.May 12 at 1:00 AM | Banyan Hill Publishing (Ad)Harrow (HROW) Projected to Post Earnings on MondayMay 9 at 3:12 AM | americanbankingnews.comHarrow, Inc. (NASDAQ:HROW) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 8, 2026 | americanbankingnews.comIs Harrow, Inc. (HROW) A Good Stock To Buy Now?April 30, 2026 | finance.yahoo.comSee More Harrow Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Harrow? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Harrow and other key companies, straight to your email. Email Address About HarrowHarrow (NASDAQ:HROW) Health, Inc. (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders. Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives. Its product portfolio includes preservative-free and compounded prescription eye drop formulations, which are distributed nationwide across all 50 states. The company leverages a targeted commercial infrastructure to support independent ophthalmologists, optometrists and surgical centers, while maintaining a research pipeline aimed at novel delivery technologies and formulations. Originally operating under the name ImprimisRx, the company officially adopted the Harrow Health name in mid-2021 to reflect its broader strategic focus on eye health. Harrow Health is led by Chairman and Chief Executive Officer Robert A. Ward, whose leadership, together with an experienced management team, has driven both commercial expansion and product innovation in the ophthalmology space.View Harrow ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MercadoLibre Boldly Invests in Growth: Discount DeepensManic Monday.com: The Rally Is Just the Beginning for this SaaS LeaderMeta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand NowTapestry Stock Drops After Strong Quarter and Raised OutlookMarketBeat Week in Review – 05/04 - 05/08Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major PlayersRocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Upcoming Earnings Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026)Applied Materials (5/14/2026)Brookfield (5/14/2026)National Grid Transco (5/14/2026)NU (5/14/2026)Mizuho Financial Group (5/15/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
